San Diego’s Illumina announced it will partner with a Chinese company to develop novel and hereditary disease testing for China.

Illumina called the collaboration a “significant step” toward China Food and Drug Administration review and approval, and a starting point to deliver precision medicine to patients throughout China.

Under the agreement, Illumina and KingMed Diagnostics will co-develop an NGS system for molecular oncology and hereditary cancer testing, based on Illumina’s MiniSeq technology and KingMed’s preparation kits and analysis software.

One goal is to reach cancer patients across China via KingMed’s extensive clinical network, spanning 8,000 hospitals.

“KingMed Diagnostics’ motivation is to improve diagnosis and treatment for the more than 4 million new cancer patients identified in China each year,” said Yaoming Liang, chairman and CEO of KingMed.